Beyfortus® logo

Menu

Get ready for the 2024/2025 RSV season


The Beyfortus® (nirsevimab-alip) Reservation Program

Optimize Your Planning for the 2024/2025 RSV Season

Product images are representative of scale - actual size of packaging may be different.

What is the Beyfortus Reservation Program?

The Beyfortus Reservation Program provides critical insight on customer demand, and we are committed to prioritizing fulfillment of requests placed through this program.


With AstraZeneca, we are expanding the Beyfortus manufacturing network to allow for a significant increase in supply for the 2024/2025 season and cover the entire US demand. In addition, we are producing Beyfortus well in advance of the RSV season, with the vast majority of doses available by October.



The Beyfortus Reservation Program will help to optimize planning and provide access to reserve Beyfortus ahead of the season.*

The Reservation Program unlocks additional benefits, including:
  • Priority shipping, with reserved doses set aside
  • Ability to determine your preferred monthly shipment schedule throughout the RSV season
  • An additional 2% reservation discount†
  • 90-day payment terms†

*Program not available for Vaccines for Children Program orders. Total order availability may be dependent on overall demand.
†2% Reservation Program discount and 90-day payment terms are only available to customers who have participated in phases I and II of the program. These benefits pertain to doses scheduled in July and August, as well as supplemental doses purchased throughout the season.

Please contact your representative or customer service for order modifications and/or cancellations within one week prior to shipment.

Here's how it works

Feb. 5, 2024 – May. 17, 2024

First, click the "Request a Representative" button above or below and fill out the form. Make sure to check the box next to "Yes, I want to participate in the Reservation Program".



Then click "Get in touch" and a representative will reach out to you soon after. They'll work with you to accurately project and submit the amount of Beyfortus you will need using the Forecast Tool.

Leveraging your historical 2023 birth data, the Sanofi representative will help estimate your total doses of 50 mg and 100 mg each as appropriate for your practice, and will generate a summary for your records.


Using the Forecast Tool

The Forecast Tool will help predict your Beyfortus needs for the upcoming RSV season.

To help calculate the doses you’ll need for a full RSV season, you will input:

  • An estimate of the number of newborns you see monthly based on your 2023 EHR data
  • The anticipated immunization rate for these newborns in your practice
  • The percentage of publicly insured patients you see

Jul. 1, 2024 – Aug. 31, 2024

To reserve your supply, you can go to vaccineshop.com or vaxserve.com during the reservation period or work with your Sanofi representative.



The Reservation Program offers flexibility based on your needs:

  • Determine the timing of your shipments throughout the RSV season. There is no minimum order to participate.
  • Orders placed during the reservation period can be made for any amount, but order should not exceed +10% from what you forecasted and submitted with your Sanofi representative in Phase 1.
  • Refer to your forecasted totals when planning your upcoming shipments for the season.


Remember to sign-up for the locator when placing your order.

Sept. 2024 – Feb. 2025

By placing your direct order through vaccineshop.com or vaxserve.com during the reservation period, shipments will begin to arrive as early as September 2024.

The Reservation Program has benefits, but it’s not your only chance to order

Orders can be placed outside of the Reservation Program during the normal order window from October 2024 through February 2025.

  • Go to vaccineshop.com or vaxserve.com and place an order as you usually would
  • Normal ordering window terms and conditions:

    - Order Now/Ship Now Only: no ability to schedule future shipments

    - Payment terms are limited to 60 days

Total order availability may be affected by overall demand.

Thanks for planning ahead for the 2024/2025 RSV season!

Important Safety Information

Contraindication
Beyfortus is contraindicated in infants and children with a history of serious hypersensitivity reactions, including anaphylaxis, to nirsevimab-alip or to any of the excipients.

Warnings and Precautions
  • Hypersensitivity Reactions Including Anaphylaxis: Serious hypersensitivity reactions have been reported following Beyfortus administration. These reactions included urticaria, dyspnea, cyanosis, and/or hypotonia. Anaphylaxis has been observed with human immunoglobulin G1 (IgG1) monoclonal antibodies. If signs and symptoms of anaphylaxis or other clinically significant hypersensitivity reactions occur, initiate appropriate treatment.

  • Use in Individuals with Clinically Significant Bleeding Disorders: As with other IM injections, Beyfortus should be given with caution to infants and children with thrombocytopenia, any coagulation disorder or to individuals on anticoagulation therapy.

Most common adverse reactions with Beyfortus were rash (0.9%) and injection site reactions (0.3%).

Indication

Beyfortus is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in:

  • Neonates and infants born during or entering their first RSV season.
  • Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

Important Safety Information

Indication

MAT-US-2310578-v5.0-07/2024